Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received a Complete Response Letter (CRL) from the FDA concerning their Biologics License Application for somatrogon, a once-weekly treatment for pediatric growth hormone deficiency (GHD). Pfizer will collaborate with the FDA to address the feedback. Despite the setback, somatrogon has gained approvals in several countries, including Japan, Canada, and Australia. The European Commission decision is expected soon. The companies remain committed to advancing somatrogon and addressing unmet medical needs in GHD.
OPKO Health and Pfizer Japan announced the approval of NGENLA®, a once-weekly treatment for children with growth hormone deficiency (GHD), approved by Japan's Ministry of Health. This long-acting recombinant human growth hormone reduces injection frequency from daily to weekly, enhancing convenience for patients. The approval is based on positive outcomes from two Phase 3 clinical studies, showing comparable efficacy to GENOTROPIN. NGENLA® was well tolerated, marking a significant development in pediatric GHD treatment.
OPKO Health, Inc. (NASDAQ: OPK) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The company will engage in one-on-one meetings with investors and host a virtual fireside chat on January 12 at 3:00 p.m. ET. The chat will be webcast live, with a replay available on OPKO's website.
OPKO is a biopharmaceutical and diagnostics firm focused on leveraging its proprietary technologies for growth in rapidly expanding markets.
OPKO Health, Inc. (NASDAQ: OPK) announced preliminary results from its Phase 2 trial of RAYALDEE for mild-to-moderate COVID-19, indicating that enhanced vitamin D status can expedite the resolution of respiratory symptoms. The trial involved 171 symptomatic COVID-19 outpatients and observed a significant increase in serum 25D levels, reaching 82 ng/mL by Day 7. Patients treated with RAYALDEE also experienced a faster resolution of respiratory symptoms, with chest congestion resolving 3.4 days earlier compared to placebo. No significant safety concerns were noted during the study.
OPKO Health, Inc. (NASDAQ: OPK) announced FDA approval of its 4Kscore Test for men 45 and older with abnormal PSA levels or DRE results. This test assesses aggressive prostate cancer risk prior to biopsy. The 4Kscore Test has been used in over 300,000 assessments since 2014 and is incorporated in major cancer guidelines. Developed using data from over 30,000 samples, it provides a numerical score based on PSA biomarkers and other patient information, aiming to improve diagnostic accuracy in prostate cancer.
OPKO Health, Inc. (NASDAQ: OPK) announced the passing of Director Richard A. Lerner, M.D., on December 2, 2021, at the age of 83. Dr. Lerner served on the Board since 2007, contributing significantly to the company and the scientific community. He was an esteemed leader at The Scripps Research Institute, enhancing its stature in biomedical research. His accolades include multiple prestigious awards and numerous patents. OPKO’s management expressed deep condolences and recognized Dr. Lerner’s invaluable contributions, marking a significant loss for the company and the industry.
BioReference Laboratories, part of OPKO Health (NASDAQ: OPK), announced its preparedness for COVID-19 testing in light of the Omicron variant. Their PCR tests remain effective, targeting RNA genes that are consistent across all coronavirus variants. Despite changes in the Spike protein associated with the Omicron variant, BioReference confirms that diagnosis capabilities remain intact, with over 19 million PCR tests conducted. The company operates four lab facilities and over 200 rapid testing sites nationwide, emphasizing a commitment to maintain and potentially increase testing capacity as needed.
OPKO Health, Inc. (NASDAQ: OPK) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The company will provide a pre-recorded fireside chat accessible to registered attendees. On December 1, management will be available for one-on-one virtual meetings with investors, which can be arranged through Piper Sandler. OPKO aims to excel in large, rapidly growing markets through its biopharmaceutical and diagnostics expertise and proprietary technologies. For further details, visit www.opko.com.
OPKO Health reported its Q3 2021 results, highlighting a revenue drop to $385.8 million from $428.1 million in Q3 2020. Operating income surged 72% to $37.8 million.
Notably, NGENLA™ was approved in Canada for pediatric growth hormone deficiency, with global applications ongoing. BRL processed 2.2 million COVID-19 PCR tests but saw a decline in testing volume. RAYALDEE revenues rose to $8.5 million. Cash and equivalents totaled $148.6 million as of September 30, 2021.
OPKO Health, Inc. (NASDAQ: OPK) is set to release its financial results for Q3 2021 after market close on October 28, 2021. The conference call with senior management will begin at 4:30 PM ET on the same day, offering a detailed business update and financial guidance. Participants can pre-register for the call or listen via a live webcast. A replay of the call will be available on OPKO's website. The company focuses on establishing leading positions in biopharmaceuticals and diagnostics through innovative technologies.